文献速递妇科

医学合并症与治疗差异是否影响上皮性卵巢癌的种族生存差异

Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
PubMed 文献 · Gynecol Oncol · 2018-01-01

在美国国家癌症研究所指定的综合性癌症中心,回顾性分析2004—2009年诊断并接受治疗的上皮性卵巢癌女性367例,其中黑人54例(15%)、白人308例(84%)。黑人患者体重指数更高、最佳肿瘤细胞减灭率更低、腹腔化疗率更低且Charlson合并症指数评分更高;校正这些差异后,黑人种族仍独立与更差的总生存相关(HR 1.61,95%CI 1.06-2.43)。

要点

  • 黑人患者较白人患者最佳手术细胞减灭率更低、腹腔化疗率更低、合并症指数评分更高。
  • 黑人较白人中位无进展生存9.7个月 vs 14.6个月(p=0.033),中位总生存21.7个月 vs 42.6个月(p<0.001)。
  • 多因素分析校正合并症与治疗差异后,黑人种族仍独立与更差总生存相关(HR 1.61,95%CI 1.06-2.43)。

核心结论

  • 在该队列中,种族差异可能源于更高的医学合并症与更低的最佳手术细胞减灭率。
  • 在考虑这些差异后,种族仍是更差总生存的独立预测因素。

研究设计与样本

  • 回顾性综述,纳入2004—2009年诊断并在本机构接受治疗和随访的上皮性卵巢癌女性。
  • 共367例符合纳入标准,其中黑人54例(15%)、白人308例(84%)。
  • 收集人口学、合并症(按Charlson合并症指数定义)、肿瘤特征、治疗、无进展生存与总生存资料。
  • 生存分析采用Kaplan-Meier法并以log-rank检验比较,多因素分析采用Cox比例风险模型。

主要发现

  • 与白人女性相比,黑人女性体重指数更高、最佳手术细胞减灭率更低、腹腔化疗率更低、Charlson合并症指数评分更高。
  • 黑人女性与白人女性的中位无进展生存分别为9.7个月与14.6个月(p=0.033)。
  • 黑人女性与白人女性的中位总生存分别为21.7个月与42.6个月(p<0.001)。
  • 多因素分析中,黑人种族独立与更差总生存相关(HR 1.61,95%CI 1.06-2.43)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Population-based studies of women with epithelial ovarian cancer suggest that black women have worse survival compared to white women. The primary objective of this study was to determine if, at a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center (CCC) serving a diverse racial and socioeconomic population, race is independently associated with differences in survival. METHODS: A retrospective review of women with EOC diagnosed between 2004-2009 undergoing treatment with follow-up at our institution was performed. Records were reviewed for demographics, comorbidities (as defined by the Charlson Comorbidity Index (CCI)), tumor characteristics, treatment, progression-free (PFS), and overall survival (OS). Survival was calculated using the Kaplan-Meier method and compared with the log-rank test. Multivariate survival analysis was performed with Cox (proportional hazards) model. RESULTS: 367 patients met inclusion criteria. 54 (15%) were black and 308 (84%) were white. Compared to white women, black women had higher BMI, lower rates of optimal surgical cytoreduction, lower rates of intraperitoneal chemotherapy, and higher CCI scores. The median PFS for black and white women were 9.7 and 14.6months, respectively (p=0.033). The median overall survival was 21.7months for black women and 42.6months for white women (p<0.001). On multivariate analysis, black race independently correlated with a worse overall survival (HR 1.61, 95% CI 1.06-2.43). CONCLUSION: In this cohort, racial disparities may be due to higher medical comorbidities and lower rates of optimal surgical cytoreduction. After accounting for these differences, race remained an independent predictor of worse overall survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dilley S, Erickson BK, Phillips CE, et al. Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer? Gynecol Oncol. 2018. PMID: 29605050. doi:10.1016/j.ygyno.2017.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。